Tu et al. performed CRISPR-Cas9 encapsulated in nanoparticles to specifically knock out cyclin-dependent kinase 5 (Cdk5) gene [69], thereby significantly reducing PD-L1 expression in tumor cells. The gene discussed is CDK5; the disease is neoplasm.